XTX-202 is under clinical development by Xilio Therapeutics and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XTX-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XTX-202 is under development for the treatment of advanced solid tumors including metastatic renal cell carcinoma, ovarian cancer, non-small cell lung cancer, squamous cell skin carcinoma and metastatic melanoma. The drug candidate targets IL2 cytokine. The drug candidates are based on Aklusion and Switchblade platform technology. It is administered through intravenous route.
Xilio Therapeutics overview
Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, the US.
For a complete picture of XTX-202’s drug-specific PTSR and LoA scores, buy the report here.